SITE003-0163

SITE003 (CAN) › SITE003-0163

SITE003-0163

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2026-03-12

enrolled

AEs

5

Serious

0

Dropout signal

–

Adverse events

5

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-18 (study day 87); relationship: NOT RELATED

moderate assessed

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-12-12 (study day 81); relationship: not assessed

mild assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-09 (study day 48); relationship: NOT RELATED

mild assessed

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-10-09 (study day 17); relationship: not assessed

mild assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-10-07 (study day 15); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.